Table 3.
Ratios between GMTs to each DENV serotype at 28 days (D56) after the second vaccine dose and before vaccination (PRE) (A); between 12 months after the second vaccine dose (M13) and PRE (B); and between M13 and D56 (C) (ATP cohort for immunogenicity M13)
| DENV-1 | DENV-2 | DENV-3 | DENV-4 | |
|---|---|---|---|---|
| A. D56/PRE GMTs | ||||
| 1 μg + alum (N = 15) | 2.29 | 2.31 | 1.91 | 2.20 |
| 4 μg + alum (N = 15) | 2.05 | 2.55 | 2.59 | 2.45 |
| 1 μg + AS01E (N = 14) | 3.64 | 3.31 | 3.66 | 5.28 |
| 1 μg + AS03B (N = 17) | 4.18 | 4.71 | 6.13 | 4.72 |
| Placebo (N = 17) | 1.08 | 0.92 | 0.92 | 1.00 |
| B. M13/PRE GMTs | ||||
| 1 μg + alum (N = 15) | 1.80 | 1.52 | 1.15 | 1.42 |
| 4 μg + alum (N = 15) | 1.99 | 2.09 | 1.51 | 1.77 |
| 1 μg + AS01E (N = 14) | 2.22 | 2.11 | 1.67 | 3.25 |
| 1 μg + AS03B (N = 17) | 3.42 | 3.70 | 3.59 | 3.22 |
| Placebo (N = 17) | 1.30 | 1.32 | 0.87 | 0.99 |
| C. M13/D56 GMTs | ||||
| 1 μg + alum (N = 15) | 0.79 | 0.66 | 0.60 | 0.65 |
| 4 μg + alum (N = 15) | 0.97 | 0.82 | 0.58 | 0.72 |
| 1 μg + AS01E (N = 14) | 0.61 | 0.64 | 0.46 | 0.62 |
| 1 μg + AS03B (N = 17) | 0.82 | 0.78 | 0.59 | 0.68 |
| Placebo (N = 17) | 1.20 | 1.43 | 0.94 | 0.98 |
1μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B; ATP = according-to-protocol; DENV = dengue virus; GMTs = geometric mean antibody titers calculated on all subjects; Postdose 2 (D56) = blood sampling 28 days postdose 2 at Day 56; Postdose 2 (M13) = blood sampling 12 months postdose 2; Prevaccination (PRE) = blood sampling prevaccination at Day 0.